NASHVILLE, Tenn., Aug. 24 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. announced today that it will report second quarter 2009 financial results before the market opens on Thursday, August 27, 2009. A conference call and live Internet webcast will be held on Thursday, August 27, 2009 at 10:00 a.m. Eastern Time to discuss the results.
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company’s primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States, and is preparing for the commercial launch of that product. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed its initial public offering of common stock in August 2009.
SOURCE Cumberland Pharmaceuticals Inc.
CONTACT: Angela Novak, Corporate Relations of Cumberland Pharmaceuticals
Inc., +1-615-255-0068, anovak@cumberlandpharma.com; or Kathy Waller of
Financial Relations Board, +1-312-543-6708, for Cumberland Pharmaceuticals
Inc.
Web site: http://www.cumberlandpharma.com/
